Kornimate/medical-research-clean huggingface dataset:
case control study to identify modifiable risk factors for colorectal and breast cancer in nigeria

Conditions: Colorectal Cancer; Breast Cancer

Summary: this project is a case-control study which seeks to identify modifiable risk factors for breast and colorectal cancer in nigeria. both cases and controls will be required to complete a risk factor questionnaire which contains information about their diet, physical activity, past medical history and life style factors. they will also be required to provide information on their body composition through the use of a bioimpedance machine which measures the body mass index, fat and total body water percentage. based on the existing argo platform where a current colorectal cancer study is going on, approximately 400 patients with a prior diagnosis or a new diagnosis will be recruited into this study. comparatively, we will select our 400 controls from two groups of participants who are free of cancer and gastrointestinal diseases.


Eligibility criteria:
case group - patients must have histologically confirmed diagnosis of colorectal or breast cancer. control group - patients must not have a diagnosis of cancer.
individualised dose optimisation of ganciclovir in immunocompromised children trial (id-magic)

Conditions: Cytomegalovirus Viraemia

Summary: this study is being conducted at seven major children's hospitals in australia and new zealand to test a new approach for treating a virus, called cytomegalovirus in children with weakened immune systems. the researchers want to find out if using a web app to customise the dose of a medication called ganciclovir is better at clearing the virus over a six-week period compared to the standard method of giving the medication.

immunocompromised children between 1 months to 18 years with cytomegalovirus viraemia who are admitted to one of the participating sites will be enrolled into the trial if eligible (see eligibility criteria) and randomly allocated into two groups. children in the 'control- standard dosing group' will receive standard intravenous ganciclovir treatment for cytomegalovirus viraemia at a standard dosing of at 5mg/kg iv bd. children in the "intervention: individualised dosing using a web app group" will receive a personalised intravenous ganciclovir dose calculated using an individualised iv ganciclovir dosing app. this approach considers the patient's weight, creatinine level, and target drug exposure, allowing for tailored dosing based on individual pharmacokinetic parameters. the virological clearance by 6 weeks of the children in each of the two groups will be compared.

Eligibility criteria:
inclusion criteria: 1. immunocompromised patients including transplant recipients (haematopoietic stem cell transplant (hsct), solid organ transplant (sot)), those receiving chemotherapy or other immunosuppression or those with a known/suspected inborn error of immunity (determined by an immunologist); and 2. detectable clinically significant cmv viraemia and treating clinician determines that antiviral therapy is indicated. 3. willing to partake in the trial 4. willing/able to attend all follow up visits and capable of completing all trial assessments. 5. legally acceptable parent/guardian capable of providing consent on the participant's behalf. 6. treating clinician agreeable to child being enrolled in the trial. exclusion criteria: 1. current or prior cmv infection with documented genotypic resistance to gcv (ul97 and/or ul54); or 2. severe renal impairment (defined as estimated glomerular filtration rate (egfr) \<25ml/min); or 3. congenital cmv infection; or 4. life expectancy of less than 7 days as determined by the treating physician; or 5. history of allergy, or adverse reaction to gcv, aciclovir or any component of the formulation; or 6. treating clinician determines that combination antiviral therapy is indicated for cmv infection; or 7. has received \>3 days of iv gcv or foscarnet or oral valganciclovir for the treatment of cmv infection prior to enrolment; or 8. prior enrolment in the trial; or 9. current recipient of another investigational product used for the treatment of cmv infection, as part of a clinical trial.
a weight maintenance study in obese patients (0364-012)(terminated)

Conditions: Obesity

Summary: to compare the effects of taranabant versus placebo on weight regain and weight maintenance after low calorie diet-induced weight loss in obese patients.


Eligibility criteria:
inclusion criteria: * patient has a body mass index (bmi) between 30 kg/m² and 43kg/m² and has maintained a stable weight (+/- 3kg) for at least 3 months prior to study start * patient is male or female \>=18 and \<= 65 years of age * patient understands the study procedures and alternative treatments available * patient is able to read, understand and complete study questionnaires exclusion criteria: * patient has a history or presence of a major psychiatric disorder * patient has a recent history (within 6 months prior to signing the informed consent) diagnosis/episode/recurrence of stroke, tia or neurological disorder * patient has a history of seizures or is at high risk of developing seizures * patient has systolic blood pressure \>160mm hg or diastolic blood pressure \> 100 mm hg * patient has diabetes mellitus as defined by medical history

Keywords: weight loss weight regain weight maintenance
the prevalence of soft tissue calcifications in the head and neck region using cbct among egyptian population

Conditions: Oral Soft Tissue Conditions

Summary: prevalence of soft tissue calcifications in the head and neck region is not clearly studied in the egyptian population. determining the incidence of these calcifications can improve the knowledge of dental practitioners and allow such practitioners to initiate proper diagnostic. and if patients need treatment they can start early by the right therapy to stop the. the aim of this research is to detect and quantify the prevalence of the soft tissue calcifications by cone beam computed tomography (cbct) images of the head and neck region in the egyptian population.

calcification of various structures located in the head and neck region are reported in patients seeking dental care. although most of the soft tissue calcification within the head and neck region might not be accompanied by clinical symptoms; the investigators should not assume that their detection do not has a strong clinical significance . some soft tissue calcification may suggest the presence of a systemic condition and may cause threatening consequences . understanding of the nature of soft tissue calcification in the head and neck helps in proper diagnosis of these calcification and in turn taking the right decision of asking for further investigation; referral or do nothing . also; many of the structures in the head and neck region are in close proximity to one another which makes identification and localization difficult and this may lead to false diagnosis . cbct is a valuable imaging modality to overcome this difficulty. the data collection for this study will be obtained from the data base available at the oral and maxillofacial radiology department at the faculty of dentistry -cairo university the following information will be recorded for each patient by : 1. age of the patient at the time of the scan . 2. sex (male or female). 3. type of the scan (mandible only, maxilla and mandible, and full scan). * assessment will be made for the following; 1. presence or absence of calcification. 2. type of calcification present (or what is this soft tissue structure). 3. side (i.e. unilateral or bilateral and what side) . 4. single or multiple occurring. * during assessing the cbct images; neither clinical information nor demographic data of the patients will be available to any of the two radiologists. * then inter-observational and intra-observational variability between the observers will be evaluated.

Eligibility criteria:
inclusion criteria: * cbct scans of 0.2 mm voxel size will be included * scans that clearly show mandible only; maxilla only; maxilla and mandible or whole face will be included. * patients age 10-80 years old . exclusion criteria: * • images with (field of view) show only one tooth or teeth. * images of poor quality will be excluded. * images showing artifacts caused by metallic implants or osteosynthesis plates. * images subjected to patient movement during acquisition will be excluded also.

Keywords: prevalence soft tissue calcification in head and neck
incidence of flare-ups and apical healing after single-visit or two-visits treatment.

Conditions: Pain

Summary: aim to compare incidence of flare-ups and apical healing after single-visit or two-visits treatment of teeth with necrotic pulp and apical periodontitis after a two-year control period. 110 teeth with a diagnosis of pulp necrosis and apical radiolucency at the apex. working length was established with eal and confirmed radiographically. m4 system with flex-r files were used to complete canal preparation. level of discomfort were recorded and cases with severe postoperative pain and/or swelling were classified as flare-ups.

110 teeth with a diagnosis of pulp necrosis and apical radiolucency at the apex. working length was established with eal and confirmed radiographically. m4 system with flex-r files were used to complete canal preparation. level of discomfort were recorded and cases with severe postoperative pain and/or swelling were classified as flare-ups.

Eligibility criteria:
inclusion criteria: * a) radiographic evidence of apical periodontitis (minimum size ≥2.0 mm x 2.0 mm) and a diagnosis of pulpal necrosis confirmed by negative response to hot and cold tests and b) need for retreatment. thermal pulp testing was performed by the author, and radiographic interpretation was verified by one certified oral surgeon. exclusion criteria: * patients without inclusion requirements or failure to obtain patient´s authorization. patients, were excluded if they were younger than 18 years old, pregnant, had a positive history of antibiotic use within the past month, suffered from diabetes, or other systemic diseases. teeth with periodontal pockets deeper than 4 mm also were excluded of the study.

Keywords: pain
mycophenolate mofetil for the prophylaxis of graft-versus-host disease in high risk allogeneic stem cell transplantation

Conditions: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation

Summary: there is a significant (50-80%) risk of acute graft-versus-host disease(gvhd) and early mortality (30%) associated with high risk stem cell transplantation (sct) such as that from a matched unrelated donor or hla-mismatch sibling. mycophenolate mofetil (mmf) has been shown to be an effective and safe immunosuppressant in the prevention and treatment of rejection after solid organ transplantation. its role in acute gvhd prophylaxis in high risk sct will be investigated in this clinical trial.


Eligibility criteria:
inclusion criteria: * patients undergoing allogeneic sct with high risk of acute gvhd, ie. from matched unrelated donor or one hla-locus mismatch sibling exclusion criteria: * known allergy to mycophenolate mofetil

Keywords: acute graft-versus-host disease post high risk allogeneic stem cell transplantation
intravesical bupivacaine on post-operative ureteroscopy pain

Conditions: Nephrolithiasis

Summary: post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. the use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the effect of instilling bupivacaine in the bladder following ureteroscopy. this is a randomized study that will investigate the effect of instilling bupivacaine in the bladder following routine ureteroscopy, laser lithotripsy and ureteral stenting in the treatment of stone disease. compared to a placebo of normal saline, our study hypothesizes that administration of topical bupivacaine in the bladder will decrease post-operative pain and lower urinary tract symptoms while improving quality of life in the early post-operative period.


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study. * male or female, aged ≥ 18 years old. * diagnosis of nephrolithiasis planned for flexible or semi-rigid ureteroscopy in the treatment of stone disease with ureteral stenting. exclusion criteria: * foley catheterization * history of allergy to bupivacaine * antegrade ureteroscopy * transplant or ectopic kidney * ureteral or bladder reconstruction * pregnancy (which is a contraindication to elective ureteroscopy) * dialysis * surgical complication (significant bleeding, ureteral perforation, significant urothelial damage) * suspicion of untreated urinary tract infection * history of pelvic radiation * neurologic disease with a diagnosis of neurogenic bladder dysfunction * history of chronic pain (fibromyalgia, interstitial cystitis, opioid abuse)
immunogenicity study of vacc-4x versus placebo in patients infected with hiv

Conditions: HIV I Infection

Summary: current management of hiv infection includes anti-retroviral therapy (art). art cannot cure the infection, making it a life-long treatment that requires sustained patient compliance and imposes significant individual and societal financial burdens on healthcare services. furthermore, art side effects often require medication that increases the inconveniences and financial burdens of hiv management. of further concern is the emergence of viruses resistant to art that can result in treatment failure. art-free periods could provide substantial benefit. vacc-4x is a peptide-based hiv immunotherapy that is proposed for prolongation of art-free periods. the purpose of this study is to determine whether vacc-4x immunotherapy can give safe art-free period.

current management of hiv infection includes anti-retroviral therapy (art). art cannot cure the infection, making it a life-long treatment that requires sustained patient compliance and imposes significant individual and societal financial burdens on healthcare services. furthermore,art side effects often require medication that increases the inconveniences and financial burdens of hiv management. of further concern is the emergence of viruses resistant to art that can result in treatment failure. art-free periods could provide substantial benefit. vacc-4x is a peptide-based hiv immunotherapy that is proposed for prolongation of art-free periods. the purpose of this study is to determine whether vacc-4x immunotherapy can give safe art-free period.

Eligibility criteria:
inclusion criteria: * age 18-55 * hiv positive at least one year * clinically stable on art for at least six months * documented viral load less than 50 copies/ml for the last six months * documented prestudy cd4 cell count equal or more than 400x10exp6/l * nadir cd4 cell count equal or more than 200x10exp6/l * signed informed consent exclusion criteria: * reported pre-study aids-defining illness within the previous year * malignant disease * on chronic treatment with immuno-suppressive therapy * unacceptable values of hematology and clinical chemistry parameters * current chronic infection such as hcv and hbv or active tuberculosis * pregnant or breastfeeding women * not using safe contraceptive methods * participation in other clinical trial * incapability of compliance
real-world treatment patterns and patient reported outcome in copd (remind)

Conditions: COPD

Summary: this retrospective observational study aims to report distribution of the proportion of symptomatic chronic obstructive pulmonary disease (copd) patients classified by the copd assessment test (cat) managed with single or dual inhaler treatment using the data at cohort entry in the copd cohort study, and treatment change and longitudinal cat score by each inhaler treatment will also be evaluated using the data during the follow-up period.


Eligibility criteria:
inclusion criteria: * patients taken with any of following inhaler treatments; lama, lama+laba(both single and dual inhaler) or ics+laba(both single and dual inhaler) at cohort entry exclusion criteria: * patients enrolled at the sites participated in the copd cohort study where not agreed on secondary use of data for this study
laparoscopic versus open appendectomy prospective randomized control study

Conditions: Appendicitis Acute

Summary: laparoscopic versus open appendectomy prospective randomized control study.both surgical methods are safe and well established in clinical practice but there has been a controversy about which surgical procedure is the most appropriate in this research we are going to demonstrate which operative procedure is more beneficial with less disadvantages.

a double-blind study is one in which neither the participants nor the experimenters know who is receiving a particular treatment. this procedure is utilized to prevent bias in research results. using envelopes as an allocation concealment method. each patient will receive two envelopes one contain paper which determine that patient will have open surgery and the other determine that patient will have lap surgery and neither patient nor experimenters know about them and patient shall choose one of them which will determine what surgery will patient undergo .

Eligibility criteria:
inclusion criteria: 1. patient age between 5-50 year old 2. patient diagnosed as acute appendicitis exclusion criteria: 1. pregnacy 2. perforated appendix 3. severe obese patient 4. previous abdominal exploration

Keywords: laparoscopic appendectomy
tranexamic acid in breast esthetic surgery.

Conditions: Hemorrhage; Bleeding

Summary: the investigators prepared a novel tranexamic acid (txa) study designed to estimate the quantity of blood loss in patients undergoing breast esthetic surgery. this study aims to quantify blood loss during abdominoplasty with and without txa. the central hypothesis is that txa administration reduces blood loss and fibrinolysis in breast esthetic surgery patients.

tranexamic acid (txa) treatment is increasingly emphasized in plastic surgery because txa inhibits fibrinolysis. increased clot stability offers the possibility of preventing blood loss (prevention) and mitigating ongoing hemorrhage. txa therapy has been principally studied in populations; the results of studies in plastic surgery still need to be improved. tranexamic acid is an antifibrinolytic agent that acts as a competitive inhibitor at the lysine binding sites of plasminogen and inhibits the ability of protease plasmin to cleave the fibrin clot. in large randomized controlled trials, it has been reported to be effective in decreasing perioperative blood loss in various circumstances, primarily involving trauma patients. the investigators designed a randomized placebo-controlled trial comparing txa dosing before incision for breast esthetic surgery. the purpose is to quantify blood loss during plastic surgery with and without txa.

Eligibility criteria:
inclusion criteria: * women scheduled for breast esthetic surgery * asa 1 or 2 * age \>18 and \<75 years exclusion criteria: * bmi \ 35 kg/m2 * asa 3 or \> 3 * medical history of thromboembolism * history of hematological disease * treatment with aspirin 14 days before the procedure * treatment with anticoagulants 5 days before the procedure * epilepsy * allergy to tranexamic acid * coagulation disorders
retrospective study of patients with severe aplastic anemia who relapsed after immunosuppressive therapy

Conditions: Severe Aplastic Anemia

Summary: background: severe aplastic anemia (saa) is a form of bone marrow failure. it usually results from a cytotoxic t cell attack on the marrow stem cell. two treatments can be used for most people with saa. one is allogeneic hematopoietic stem cell transplant (hsct). the other is immunosuppressive treatment (ist). for people who are treated with ist, relapse can occur. if this happens, they can have hsct or be re-treated with ist. the two most common ist regimes used for relapsed saa are rabbit atg (ratg) and alemtuzumab. both ratg and alemtuzumab have similar response rates and survival rates. there is not much long-term data on people who need repeat ist treatment due to relapse. researchers want to look at data from past studies to learn more. objective: to compare the data of relapsed saa patients between those who received alemtuzumab versus ratg for repeat ist treatment. eligibility: adults and children with saa who were enrolled on nhlbi protocol 12-h-0150, 06-h-0034, 05-h-0242, 03-h-0249, 03-h-0193, 00-h-0032, or 90-h-0146 design: this study uses data from past studies. the participants in those studies have allowed their data to be used in future research. researchers will review participants medical records. they will collect clinical data, such as notes, test results, and imaging scans. they will also collect the research data gathered as part of the original study. researchers will enter the data into an in-house database. it is password protected. all data will be kept in secure network drives or in secure sites. other studies may be added in the future....

severe aplastic anemia (saa) is a form of bone marrow failure and in most cases is the result of a cytotoxic t cell attack on the marrow stem cell. it is effectively treated in most patients with either immunosuppressive treatment (ist) or upfront allogeneic hematopoietic stem cell transplant (hsct). however, in patients who are treated with ist, relapse remains an issue with a rate of 30-40%. once relapsed, patients can be either re-treated with ist or undergo hsct. the two most common ist regimes used for relapsed saa are rabbit atg (ratg) and alemtuzumab. both ratg and alemtuzumab have been shown to have a response rate of approximately 60% in relapsed patients with similar overall survival rates of 83-85%. previous predictors of relapse include time from diagnosis to ist, and early response to ist. few long-term data exist on patients requiring repeat ist treatment due to relapse.

Eligibility criteria:
* this is a retrospective chart review. the investigators will review the medical records of adults and children with severe aplastic anemia (saa) enrolled on immunosuppressive therapy (ist) treatment protocols in the nhlbi. patients who opted out of future use of data on their prior studies will be excluded from this study.

Keywords: alemtuzumab ratg natural history
concordance of three imaging methods by dynamic ct, contrast ultrasound and ct angiography in the characterization of endoleaks in patients with an aortic endoprosthesis

Conditions: Aortic Diseases

Summary: among patients who have undergone evar, there is a significant risk of 20-50% endoleak. these endoleaks often require secondary interventions to reduce the risk of expansion or rupture. currently, three-phase ct angiography and ceus ultrasound are recommended in the post-operative monitoring of evar but these remain limited in characterizing the type and source of endoleak. in this study the investigators will study the interest of d-cta for a better detection and characterization of endoleaks.


Eligibility criteria:
inclusion criteria: * patients 18 years of age and older, * patients who have received evar , * detection of endoleak and/or with an aneurysmal sac enlargement greater than or equal to 5 mm over 6 months. exclusion criteria: * minor patients, * absence of endoleak and growth of the aneurysmal sac (greater than or equal to 5 mm over 6 months), * patient under guardianship, curators, safeguard of justice, * patient deprived of liberty, * pregnant woman * patient who does not benefit from a social security scheme

Keywords: evar d-cta ceus